Theravance Biopharma TBPH Total debt

Total debt at other companies

Gyre Therapeutics, Inc.GYRE

$3.42M+145%

Rigel PharmaceuticalsRIGL

$68.36M+5,079%

LQD

Liquidia CorporationLQDA

$6.96M+1.5%

Royalty PharmaRPRX

$8.96B+11.7%

Zevra Therapeutics, Inc.ZVRA

$1.5M-97.6%

Aurinia PharmaceuticalsAUPH

$80.62M-17.7%

FAQ

What is Theravance Biopharma's total debt?

Theravance Biopharma (TBPH) reported total debt of $40.5M in Q1 2026.

How has Theravance Biopharma's total debt changed year-over-year?

Theravance Biopharma's total debt decreased by 15.9% year-over-year, from $48.16M to $40.5M.

What is the long-term trend for Theravance Biopharma's total debt?

Over 5 years (2020 to 2025), Theravance Biopharma's total debt has grown at a -5.6% compound annual growth rate (CAGR), from $57.09M to $42.7M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.